A comparative evaluation of sacubitril-valsartan and nebivolol-valsartan in left ventricular remodeling following chronic myocardial infarction in female Wistar rats.
Saved in:
| Title: | A comparative evaluation of sacubitril-valsartan and nebivolol-valsartan in left ventricular remodeling following chronic myocardial infarction in female Wistar rats. |
|---|---|
| Alternate Title: | Evaluación comparativa de sacubitril-valsartán y nebivolol-valsartán en la remodelación ventricular izquierda tras un infarto de miocardio crónico en ratas Wistar hembras. |
| Authors: | Pérez-García, Erika1, Valencia-Hernández, Ignacio2, Lezama-Martínez, Diego3, Ramírez-Hernández, Diana3, Garrido-Fariña, Germán Isauro4, Ramírez-Hernández, César5, Reyes-Alvarado, Karla5, Hidalgo, Isabel6, Flores-Monroy, Jazmín3 jfmqfb@cuautitlan.unam.mx |
| Source: | Cardiovascular & Metabolic Science. Apr-Jun2026, Vol. 37 Issue 2, p60-73. 14p. |
| Subjects: | Ventricular remodeling, Myocardial infarction, Heart failure, Laboratory rats, Heart fibrosis, Combination drug therapy, Entresto |
| Abstract (English): | Cardiac fibrosis following a myocardial infarction (MI) leads to adverse left ventricular remodeling and heart failure, with distinct patterns observed in women. Despite having smaller infarcts and less profibrotic activity, women have a higher risk of post-MI mortality and heart failure. Since on therapies currently target fibrosis directly, studying these mechanisms is essential for developing and testing treatments, including approved heart failure drugs such as sacubitril-valsartan. This study aimed to compare and evaluate the combination of nebivolol-valsartan (NV) vs sacubitril-valsartan (SV) as a known treatment for chronic infarction in female rats; 26-weeks-old Wistar rats were used. The animals were divided into four groups (n = 6): 1) control (SHAM); 2) myocardial infarction (LADL); 3) LADL + sacubitril 30 mg/kg/day + valsartan 28 mg/kg/day (LADL + SV); 4) LADL + valsartan 30 mg/kg/day + nebivolol 5 mg/kg/day (LADL + NV). Infarct induction was performed by permanent ligation of the left anterior descending coronary artery. The treated groups received their treatments right after infarct induction for two weeks. The rats were euthanized by cervical dislocation and hearts and lungs were obtained from all groups for histology using Van Gieson and HE staining. The NV combination resulted in 50% mortality in animals, promoting pulmonary congestion and pleural effusion. Therefore, the administration of the NV combination at different times was proposed, after three and seven days post-infarction. This resulted in six experimental groups. There was a reduction in the mortality rate, reduction of hypertrophy and cardiac fibrosis when the NV combination was administered seven days after ligation. In conclusion, sacubitril-valsartan appears to be a safe and effective strategy to attenuate cardiac and pulmonary fibrosis after infarction female rats, however, based on the results, early administration of nebivololvalsartan is not recommended, as it appears to increase the risk of post-infarction complications. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | La fibrosis cardiaca tras un infarto de miocardio (IM) provoca una remodelación ventricular izquierda adversa e insuficiencia cardiaca, observándose patrones distintos en las mujeres. A pesar de presentar infartos de menor tamaño y una menor actividad profibrótica, las mujeres tienen un mayor riesgo de mortalidad tras un IM y de insuficiencia cardiaca. Dado que las terapias actuales se dirigen directamente a la fibrosis, el estudio de estos mecanismos es esencial para desarrollar y evaluar tratamientos, incluidos los fármacos aprobados para la insuficiencia cardiaca, como el sacubitril-valsartán. El objetivo de este estudio fue comparar y evaluar la combinación de nebivolol-valsartán (NV) frente a sacubitril-valsartán (SV) como tratamiento conocido para el infarto crónico en ratas hembras. Se utilizaron ratas Wistar de 26 semanas de edad. Los animales se dividieron en cuatro grupos (n = 6): 1) control (SHAM); 2) infarto de miocardio (LADL); 3) LADL + sacubitril 30 mg/kg/día + valsartán 28 mg/kg/día (LADL + SV); 4) LADL + valsartán 30 mg/kg/día + nebivolol 5 mg/kg/día (LADL + NV). La inducción del infarto se realizó mediante ligadura permanente de la arteria coronaria descendente anterior izquierda. Los grupos tratados recibieron sus tratamientos inmediatamente después de la inducción del infarto durante dos semanas. Las ratas fueron sacrificadas mediante dislocación cervical y se extrajeron los corazones y los pulmones de todos los grupos para su análisis histológico mediante tinción de Van Gieson y HE. La combinación de NV provocó una mortalidad de 50% en los animales, lo que favoreció la congestión pulmonar y el derrame pleural. Por lo tanto, se propuso la administración de la combinación de NV en diferentes momentos, a los tres y a los siete días tras el infarto. Esto dio lugar a seis grupos experimentales. Se observó una reducción de la tasa de mortalidad, así como de la hipertrofia y la fibrosis cardiaca, cuando la combinación de NV se administró siete días después de la ligadura. En conclusión, el sacubitril-valsartán parece ser una estrategia segura y eficaz para atenuar la fibrosis cardiaca y pulmonar tras el infarto en ratas hembras, mientras que la administración temprana de nebivolol-valsartán no se recomendaría de acuerdo a los resultados, ya que aparentemente podría generar más complicaciones postinfarto. [ABSTRACT FROM AUTHOR] |
| Copyright of Cardiovascular & Metabolic Science is the property of Cardiovascular & Metabolic Science, Asociacion Nacional de Cardiologos de Mexico A.C. (ANCAM) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 195211889 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A comparative evaluation of sacubitril-valsartan and nebivolol-valsartan in left ventricular remodeling following chronic myocardial infarction in female Wistar rats. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Evaluación comparativa de sacubitril-valsartán y nebivolol-valsartán en la remodelación ventricular izquierda tras un infarto de miocardio crónico en ratas Wistar hembras. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Pérez-García%2C+Erika%22">Pérez-García, Erika</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Valencia-Hernández%2C+Ignacio%22">Valencia-Hernández, Ignacio</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Lezama-Martínez%2C+Diego%22">Lezama-Martínez, Diego</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Ramírez-Hernández%2C+Diana%22">Ramírez-Hernández, Diana</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Garrido-Fariña%2C+Germán+Isauro%22">Garrido-Fariña, Germán Isauro</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Ramírez-Hernández%2C+César%22">Ramírez-Hernández, César</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Reyes-Alvarado%2C+Karla%22">Reyes-Alvarado, Karla</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Hidalgo%2C+Isabel%22">Hidalgo, Isabel</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Flores-Monroy%2C+Jazmín%22">Flores-Monroy, Jazmín</searchLink><relatesTo>3</relatesTo><i> jfmqfb@cuautitlan.unam.mx</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Cardiovascular+%26+Metabolic+Science%22">Cardiovascular & Metabolic Science</searchLink>. Apr-Jun2026, Vol. 37 Issue 2, p60-73. 14p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Ventricular+remodeling%22">Ventricular remodeling</searchLink><br /><searchLink fieldCode="DE" term="%22Myocardial+infarction%22">Myocardial infarction</searchLink><br /><searchLink fieldCode="DE" term="%22Heart+failure%22">Heart failure</searchLink><br /><searchLink fieldCode="DE" term="%22Laboratory+rats%22">Laboratory rats</searchLink><br /><searchLink fieldCode="DE" term="%22Heart+fibrosis%22">Heart fibrosis</searchLink><br /><searchLink fieldCode="DE" term="%22Combination+drug+therapy%22">Combination drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Entresto%22">Entresto</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Cardiac fibrosis following a myocardial infarction (MI) leads to adverse left ventricular remodeling and heart failure, with distinct patterns observed in women. Despite having smaller infarcts and less profibrotic activity, women have a higher risk of post-MI mortality and heart failure. Since on therapies currently target fibrosis directly, studying these mechanisms is essential for developing and testing treatments, including approved heart failure drugs such as sacubitril-valsartan. This study aimed to compare and evaluate the combination of nebivolol-valsartan (NV) vs sacubitril-valsartan (SV) as a known treatment for chronic infarction in female rats; 26-weeks-old Wistar rats were used. The animals were divided into four groups (n = 6): 1) control (SHAM); 2) myocardial infarction (LADL); 3) LADL + sacubitril 30 mg/kg/day + valsartan 28 mg/kg/day (LADL + SV); 4) LADL + valsartan 30 mg/kg/day + nebivolol 5 mg/kg/day (LADL + NV). Infarct induction was performed by permanent ligation of the left anterior descending coronary artery. The treated groups received their treatments right after infarct induction for two weeks. The rats were euthanized by cervical dislocation and hearts and lungs were obtained from all groups for histology using Van Gieson and HE staining. The NV combination resulted in 50% mortality in animals, promoting pulmonary congestion and pleural effusion. Therefore, the administration of the NV combination at different times was proposed, after three and seven days post-infarction. This resulted in six experimental groups. There was a reduction in the mortality rate, reduction of hypertrophy and cardiac fibrosis when the NV combination was administered seven days after ligation. In conclusion, sacubitril-valsartan appears to be a safe and effective strategy to attenuate cardiac and pulmonary fibrosis after infarction female rats, however, based on the results, early administration of nebivololvalsartan is not recommended, as it appears to increase the risk of post-infarction complications. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: La fibrosis cardiaca tras un infarto de miocardio (IM) provoca una remodelación ventricular izquierda adversa e insuficiencia cardiaca, observándose patrones distintos en las mujeres. A pesar de presentar infartos de menor tamaño y una menor actividad profibrótica, las mujeres tienen un mayor riesgo de mortalidad tras un IM y de insuficiencia cardiaca. Dado que las terapias actuales se dirigen directamente a la fibrosis, el estudio de estos mecanismos es esencial para desarrollar y evaluar tratamientos, incluidos los fármacos aprobados para la insuficiencia cardiaca, como el sacubitril-valsartán. El objetivo de este estudio fue comparar y evaluar la combinación de nebivolol-valsartán (NV) frente a sacubitril-valsartán (SV) como tratamiento conocido para el infarto crónico en ratas hembras. Se utilizaron ratas Wistar de 26 semanas de edad. Los animales se dividieron en cuatro grupos (n = 6): 1) control (SHAM); 2) infarto de miocardio (LADL); 3) LADL + sacubitril 30 mg/kg/día + valsartán 28 mg/kg/día (LADL + SV); 4) LADL + valsartán 30 mg/kg/día + nebivolol 5 mg/kg/día (LADL + NV). La inducción del infarto se realizó mediante ligadura permanente de la arteria coronaria descendente anterior izquierda. Los grupos tratados recibieron sus tratamientos inmediatamente después de la inducción del infarto durante dos semanas. Las ratas fueron sacrificadas mediante dislocación cervical y se extrajeron los corazones y los pulmones de todos los grupos para su análisis histológico mediante tinción de Van Gieson y HE. La combinación de NV provocó una mortalidad de 50% en los animales, lo que favoreció la congestión pulmonar y el derrame pleural. Por lo tanto, se propuso la administración de la combinación de NV en diferentes momentos, a los tres y a los siete días tras el infarto. Esto dio lugar a seis grupos experimentales. Se observó una reducción de la tasa de mortalidad, así como de la hipertrofia y la fibrosis cardiaca, cuando la combinación de NV se administró siete días después de la ligadura. En conclusión, el sacubitril-valsartán parece ser una estrategia segura y eficaz para atenuar la fibrosis cardiaca y pulmonar tras el infarto en ratas hembras, mientras que la administración temprana de nebivolol-valsartán no se recomendaría de acuerdo a los resultados, ya que aparentemente podría generar más complicaciones postinfarto. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Cardiovascular & Metabolic Science is the property of Cardiovascular & Metabolic Science, Asociacion Nacional de Cardiologos de Mexico A.C. (ANCAM) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=195211889 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.35366/123377 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 14 StartPage: 60 Subjects: – SubjectFull: Ventricular remodeling Type: general – SubjectFull: Myocardial infarction Type: general – SubjectFull: Heart failure Type: general – SubjectFull: Laboratory rats Type: general – SubjectFull: Heart fibrosis Type: general – SubjectFull: Combination drug therapy Type: general – SubjectFull: Entresto Type: general Titles: – TitleFull: A comparative evaluation of sacubitril-valsartan and nebivolol-valsartan in left ventricular remodeling following chronic myocardial infarction in female Wistar rats. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pérez-García, Erika – PersonEntity: Name: NameFull: Valencia-Hernández, Ignacio – PersonEntity: Name: NameFull: Lezama-Martínez, Diego – PersonEntity: Name: NameFull: Ramírez-Hernández, Diana – PersonEntity: Name: NameFull: Garrido-Fariña, Germán Isauro – PersonEntity: Name: NameFull: Ramírez-Hernández, César – PersonEntity: Name: NameFull: Reyes-Alvarado, Karla – PersonEntity: Name: NameFull: Hidalgo, Isabel – PersonEntity: Name: NameFull: Flores-Monroy, Jazmín IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: Apr-Jun2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 26832828 Numbering: – Type: volume Value: 37 – Type: issue Value: 2 Titles: – TitleFull: Cardiovascular & Metabolic Science Type: main |
| ResultId | 1 |
